Objectives To examine the effects of exposure to ceftaroline or ceftriaxone on the epidemic
Clostridium difficile strain PCR ribotype 027 and the indigenous gut microflora in an in vitro …

Objectives Fidaxomicin reduces the risk of recurrent Clostridium difficile infection (CDI)
compared with vancomycin. We investigated fidaxomicin primary or secondary treatment …

Objectives The use of broad-spectrum cephalosporins is associated with induction of
Clostridioides difficile infection (CDI). Recent knowledge on the importance of the healthy …

Objectives Clostridium difficile infection (CDI) is still a major clinical challenge. Previous
studies have demonstrated multiple distinct C. difficile strains in the faeces of patients with …

This study assessed the pharmacokinetic profiles for intramuscular and intravenous
ceftaroline treatment for rats, rabbits, and monkeys. Ceftaroline, a novel cephalosporin with …

The incidence of Clostridium difficile infection is increasing, with reports implicating
fluoroquinolone use. A three-stage chemostat gut model was used to study the effects of …

Clostridium difficile is the causative agent of C. difficile-associated diarrhea (CDAD), with
increased risk in elderly populations. Kibdelomycin, a novel natural-product inhibitor of type …

Objectives: Clostridium difficile infection (CDI) is a major cause of morbidity in the
nosocomial environment. Antimicrobial agents such as the third-generation cephalosporins …

Background Fidaxomicin treatment reduces the risk of recurrent Clostridium difficile infection
(CDI) compared with vancomycin. Extending duration of fidaxomicin therapy may further …

The kinetics of bacterial killing for fidaxomicin and its major metabolite, OP-1118, were
investigated against Clostridium difficile strains, including two clinical strains belonging to …